重药控股(000950.SZ)：子公司药物获临床试验批准

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration to conduct clinical trials for its drug, which is currently not available in China [1] Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, is set to initiate clinical trials for the drug, which is a third-generation platelet aggregation inhibitor [1] - The drug, Prasugrel Hydrochloride Tablets, is indicated for preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1] Industry Summary - The drug is already marketed in over 70 countries and regions globally, indicating its established presence in the international pharmaceutical market [1]